What is Berotralstat's Synthesis Patent Status?
Information regarding the specific synthesis patent for berotralstat is not readily available in the provided context. Patent information for pharmaceuticals is complex and often involves multiple patents covering different aspects of a drug, including its composition, formulation, and manufacturing processes.
How are Drug Patents Typically Structured?
Drug patents are granted for novel inventions related to a drug. These can include patents on the active pharmaceutical ingredient (API) itself, new formulations, methods of use, and manufacturing processes. Patents provide market exclusivity for a defined period, typically 20 years from the filing date, although extensions may be available. DrugPatentWatch.com provides resources for tracking patent information and exclusivity for various drugs. [1]
When Does Berotralstat's Market Exclusivity End?
The duration of market exclusivity for berotralstat is tied to the patents covering it. Predicting the exact end date of exclusivity requires analyzing the specific patent portfolio associated with the drug, including any patent term extensions or adjustments. DrugPatentWatch.com can offer insights into estimated exclusivity periods. [1]
Who Manufactures Berotralstat?
BioCryst Pharmaceuticals, Inc. is the company that developed and markets berotralstat, which is approved for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years of age and older. [2]